New Phase 3 Studies of Medication for Opioid-Induced Constipation (OIC) Announced

Cubist Pharmaceuticals, Inc, developers of bevenopran (previously known as CB-5945) have announced a new Phase 3 program, ASCENT, to study the efficacy and safety of the medication vs placebo in patients with chronic non-cancer pain and OIC. The program will include 3 studies enrolling approximately 600 patients each, in addition to a one-year placebo-controlled safety study involving 1,400 patients that is already underway.  Read a news report here.

Related Content